

ASH 2023 FEATURED NHLBI PRESENTATIONS

Saturday, December 9

Oral Abstract 33

[Hematopoietic Stem Cells from Mice and Individuals with Sickle Cell Disease Display Premature Senescence and Loss of Function that is Targetable By Senolytic Therapy](#)

Aditya Barve, Ph.D.

10 a.m. PT

San Diego Convention Center, Room 24

Education Program

[When to Consider Inherited Marrow Failure Syndromes in Adults](#)

Emma Groarke, M.D.

2 – 3:15 p.m. PT

San Diego Convention Center, Room 24

Oral Abstract 247

[Successful Implementation Trial to Improve Stroke Risk \(TCD\) Screening in Children with Sickle Cell Anemia: A Roadmap to Care Enhancement](#)

Julie Kanter, M.D.

2 p.m. PT

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

Oral Abstract 201

[Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-Up of a Phase 2 Study](#)

Adrian Wiestner, M.D.

2:30 p.m. PT

Manchester Grand Hyatt San Diego, Grand Hall D

Oral Abstract 150

[Enhanced Expression of Heme Oxygenase-1 \(HO-1\) Among Children with Sickle Cell Disease: Results of the Sickle Cell Disease Genomics of Africa \(SickleGenAfrica\) Study](#)

Anna Sowa, M.D.

3:15 p.m. PT

San Diego Convention Center, Room 31

Oral Abstract 273

[Long-Term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study](#)

Swee Lay Thein, M.B.B.S., D.Sc., FRCP, F.R.C.Path., M.R.C.P., M.R.C.Path.

4:30 p.m. PT

San Diego Convention Center, Room 28 A-D

Oral Abstract 345

Microbiota-Specific T Cells Contribute to Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Albert Yeh, M.D.

4:30 p.m. PT

San Diego Convention Center, Room 7

Oral Abstract 371

Assessing Psychosocial Readiness for Gene Therapy in Sickle Cell Disease: A Consensus Statement

Steven J. Hardy, Ph.D.

5 p.m. PT

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

Sunday, December 10

Oral Abstract 424

Measurable Residual IDH2 Before Allogeneic Transplant for Acute Myeloid Leukemia

Gege Gui, Sc.M.

10:15 a.m. PT

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Oral Abstract 486

CD117 Antibody-Drug Conjugate Conditioning Allows Efficient Engraftment of Gene-Modified CD34+ Cells with Fertility Preservation in a Rhesus Gene Therapy Model

Naoya Uchida, M.D., Ph.D.

10:45 a.m. PT

San Diego Convention Center, Ballroom 20CD

ASH Mentor Award

Helen Heslop, M.D., D.Sc.

1:30 – 2:30 p.m. PT

San Diego Convention Center, Hall A

ASH Award for Leadership in Promoting Diversity

Alexis A. Thompson, M.D., M.P.H.

1:30 – 2:30 p.m. PT

San Diego Convention Center, Hall A

Plenary Scientific Session 3

Synthetic Introns Identify the Novel RNA Splicing Factor GPATCH8 As Required for Mis-Splicing Induced By SF3B1 Mutations

Salima Benbarche, Ph.D.

2 – 4 p.m. PT

San Diego Convention Center, Hall A

Plenary Scientific Session 5

Metabolic Programming of Hematopoietic Stem Cell Function by Prenatal Folate

Brian Krum, M.Sc.

2 – 4 p.m. PT

San Diego Convention Center, Hall A

Plenary Scientific Session 6

Hydroxyurea Dose Optimization Is Safe and Improves Outcomes for Children with Sickle Cell Anemia Living in Sub-Saharan Africa: The Reach Experience

Banu Aygun, M.D.

2 – 4 p.m. PT

San Diego Convention Center, Hall A

Monday, December 11

Oral Abstract 703

Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome

Bhavisha Patel, M.D.

10:30 a.m. PT

San Diego Convention Center, Room 6DE

Oral Abstract 1051

Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Julie Kanter, M.D.

4:30 p.m. PT

San Diego Convention Center, Hall A

Education Program

Gene Therapy for Sickle Cell Disease

John F. Tisdale, M.D.

4:30 – 5:45 p.m. PT

San Diego Convention Center, Room 29

Oral Abstract 929

SCD Dyslipidemia Normalizes Long-Term Following Nonmyeloablative Hematopoietic Cell Transplantation

Jackie Queen, M.D., M.P.H.

5:30 p.m. PT

San Diego Convention Center, Room 31

Oral Abstract 941

[Clonal Derivation and Dynamics in Rhesus Macaques Following Hematopoietic Stem Cell Transplantation and the Impact of Clonal Hematopoiesis](#)

Yifan Zhou, M.S.

5:30 p.m. PT

San Diego Convention Center, Room 24

Oral Abstract 1062

[Identifying Geriatric Syndromes in Adults with Sickle Cell Disease Using the Sickle Cell Disease Functional Assessment \(SCD-FA\): The Sickle Cell Disease Functional Assessment Validation and Refinement \(SILVR\) Study](#)

Charity I. Oyedeki, M.D.

5:45 p.m. PT

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Tuesday, December 12

[Henry M. Stratton Medal](#)

James B. Bussel, M.D.

8:45 – 9 a.m. PT

San Diego Convention Center, Hall A

Late-Breaking Abstracts 3

[PATH-HHT, a Double-Blind, Randomized, Placebo-Controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life](#)

Keith McCrae, M.D.

9 – 10:30 a.m. PT

San Diego Convention Center, Hall A

Late-Breaking Abstracts 4

[Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell](#)

Adetola Kassim, M.B.B.S., M.S.

9:45 – 10 a.m. PT

San Diego Convention Center, Hall A

Presidential Symposium

[The Complement System and Targeted Therapies – Intracellular Complement and Adoptive Immunity](#)

Claudia Kemper, Ph.D.

11 a.m. – 12:30 p.m. PT

San Diego Convention Center, Hall A